Publications by authors named "S Paydas"
Article Synopsis
- The study examines the role of Her2 status in early stage triple negative breast cancer (TNBC) patients undergoing neoadjuvant chemotherapy, revealing conflicting results regarding its prognostic impact.
- A total of 620 female TNBC patients were analyzed, with 68.9% having Her2-0 and 31.1% having Her2-low status; the rates of pathological complete response (pCR) were similar between these groups.
- While the Her2-0 group showed better disease-free survival (DFS), the overall survival (OS) rates were similar between the two groups, indicating the need for further research into the implications of Her2 status in this treatment context.
Predictive prognostic scoring (PS) systems are not primarily applicable to elderly patients with classical Hodgkin lymphoma (cHL). The objective of this study was to develop a PS system for these patients. The derivation cohort (DC) was utilized for model development, consisting of 97 variables.
View Article and Find Full Text PDFSoft tissue sarcomas are rare cancers and most cases are metastatic at the time of diagnosis. Although the chances of survival are good with surgical treatment in the early stages, systemic treatment in the advanced stages is only associated with a survival duration of ~12 months. Alterations in the anaplastic lymphoma kinase (ALK) gene are becoming increasingly recognized as pan-cancer indicators in solid tumors.
View Article and Find Full Text PDFArticle Synopsis
- Latent tuberculosis infection (LTBI) screening is essential for solid organ transplant (SOT) recipients, but many centers in Turkey are not adequately performing these screenings.
- In a study involving 766 SOT patients, 46.9% tested positive for LTBI, but only about half of those treated were registered, and there was a low completion rate of treatment.
- The findings highlight the need for better TB risk assessment and adherence to national guidelines to improve pre-transplant care for SOT recipients in Turkey.
Objective: To evaluate the efficacy and safety of nivolumab in the second-line (2L) or later-line (LL) treatment of patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) in real-life setting in Türkiye.
Methods: This study was designed as a national, multi-center, retrospective study. The study population was evaluated in two groups for the line of nivolumab therapy: those receiving nivolumab in the 2L (Group 2L) and third-line (3L) or LL (Group 3L/LL).